{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+5", "query": { "condition": "Alzheimer Disease 5" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alzheimer+Disease+5&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T09:05:43.030Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03384316", "title": "Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Prostate Cancer", "Lung Cancer", "Breast Cancer", "Colon Cancer" ], "interventions": [ { "name": "ETBX-051; adenoviral brachyury vaccine", "type": "BIOLOGICAL" }, { "name": "ETBX-061; adenoviral Mucin-1 (MUC1) vaccine", "type": "BIOLOGICAL" }, { "name": "ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2018-01-31", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384316" }, { "nct_id": "NCT00483028", "title": "A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "donezepil (Aricept)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 38, "start_date": "2004-06", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2008-02-05", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Albany, New York", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00483028" }, { "nct_id": "NCT00119873", "title": "Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VRC-HIVADV014-00-VP", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 48, "start_date": null, "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 3, "location_summary": "San Francisco, California • Nashville, Tennessee • Seattle, Washington", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00119873" }, { "nct_id": "NCT02751528", "title": "QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ETBX-021", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NantBioScience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-03-04", "completion_date": "2018-08-16", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 2, "location_summary": "El Segundo, California • Sioux Falls, South Dakota", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02751528" }, { "nct_id": "NCT00454870", "title": "Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "MEM 3454", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memory Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2007-02", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2008-05-06", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00454870" }, { "nct_id": "NCT07417488", "title": "GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Ad5.F35-hGUCY2C-PADRE vaccine", "type": "BIOLOGICAL" }, { "name": "Lm-GUCY2C vaccine", "type": "BIOLOGICAL" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-04-21", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07417488" }, { "nct_id": "NCT00801697", "title": "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "DNA Vaccine placebo", "type": "BIOLOGICAL" }, { "name": "rAd35", "type": "BIOLOGICAL" }, { "name": "rAd35 placebo", "type": "BIOLOGICAL" }, { "name": "rAd5", "type": "BIOLOGICAL" }, { "name": "rAd5 placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 192, "start_date": "2009-02", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00801697" }, { "nct_id": "NCT04854746", "title": "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Norovirus Infections" ], "interventions": [ { "name": "VXA-GI.1.NN", "type": "BIOLOGICAL" }, { "name": "Placebo Tablet", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vaxart", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "55 Years to 80 Years" }, "enrollment_count": 66, "start_date": "2021-04-26", "completion_date": "2022-01-04", "has_results": false, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 3, "location_summary": "Cypress, California • New Orleans, Louisiana • Austin, Texas", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04854746" }, { "nct_id": "NCT05637801", "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Alzheimer Disease 1", "Alzheimer Disease 2", "Alzheimer Disease 3", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Alzheimer Disease 9", "Alzheimer Disease 4", "Alzheimer Disease 7", "Alzheimer Disease 17", "Alzheimer's Dementia Late Onset", "Alzheimer Disease 5", "Alzheimer Disease 6", "Alzheimer Disease 8", "Alzheimer Disease 10", "Alzheimer Disease 11", "Alzheimer Disease 12", "Alzheimer Disease 13", "Alzheimer Disease 14", "Alzheimer Disease 15", "Alzheimer Disease 16", "Alzheimer Disease 18", "Alzheimer Disease 19", "Dementia", "Dementia Alzheimers", "Dementia, Mild", "Dementia of Alzheimer Type", "Dementia Moderate", "Dementia Senile", "Mild Cognitive Impairment", "Mild Dementia", "MCI", "Cognitive Impairment", "Cognitive Decline", "Cognitive Impairment, Mild" ], "interventions": [ { "name": "Spectris™ AD - Active", "type": "DEVICE" }, { "name": "Spectris™ AD - Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cognito Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 670, "start_date": "2022-12-13", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 68, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05637801" }, { "nct_id": "NCT04111172", "title": "A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Colorectal Adenocarcinoma", "Gastric Adenocarcinoma", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage IIA Gastric Cancer AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastric Cancer AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Malignant Solid Neoplasm", "Pathologic Stage II Gastric Cancer AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastric Cancer AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Stage I Pancreatic Cancer AJCC v8", "Stage IA Pancreatic Cancer AJCC v8", "Stage IB Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Malignant Digestive System Neoplasm", "Small Intestinal Adenocarcinoma", "Stage III Small Intestinal Adenocarcinoma AJCC v8", "Stage IIIA Small Intestinal Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-11-10", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-05-22T09:05:43.030Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04111172" } ] }